Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease

“This is a [subset] of patients [that is] difficult to treat; they are relapsing quickly without many good [treatment] options available. From an efficacy point of view, [these data] are quite exciting for myeloma investigators.”

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic, discussed efficacy data from the phase 2 RedirecTT-1 study (NCT04586426) of talquetamab (Talvey) in combination with teclistamab (Tecvayli) in patients with relapsed/refractory multiple myeloma with extramedullary disease.

Findings from RedirecTT-1 presented during the 2025 EHA Congress revealed that the median progression-free survival (PFS) after 13 months of follow-up was 15.4 months (95% CI, 10.8-not evaluable) among patients with relapsed/refractory multiple myeloma and true extramedullary disease who received the combination (n = 90), Raza began. The 12-month PFS rate was 61.0% (95% CI, 49.6%-70.6%). Raza noted that this finding was significant because standard-of-care therapy for the treatment of this patient population usually confers a median PFS of approximately 3 months.

At a median follow-up of 12.6 months (range, 0.5-19.5), patients treated with talquetamab plus teclistamab achieved an overall response rate (ORR) of 78.9% (95% CI, 69.0%-86.8%), Raza said. The complete response or better rate was 54.4% and the very good partial response rate was 70.0%. Most patients experienced durable responses and were still responding after 1 year, Raza added.

The ORR among patients who received a prior anti-BCMA CAR-T cell therapy (n = 18) was 83.3% (95% CI, 58.6%-96.4%). Those treated with prior belantamab mafodotin (Blenrep; n = 11) or a prior anti-FcRH5 bispecific antibody (n = 8) experienced ORRs of 90.9% (95% CI, 34.9%-96.8%) and 75.0% (95% CI, 34.9%-96.8%), respectively.

Such data have not been previously reported in this patient population, Raza explained. He noted that patients with relapsed/refractory multiple myeloma with extramedullary disease have been historically difficult to treat because they are experiencing disease relapse quickly and do not have many good treatment options. These data are exciting for patients and investigators, he concluded.